News

Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting

Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for the potential treatment of neurological disorders, today will present updated preliminary data from its ongoing open-label Phase 1/2 clinical trial of NRTX-1001 in adults with drug-...

Exai Bio to Present New Breast Cancer Data at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting. In a new study, Exai’s novel RNA- and AI-based liquid biopsy platform demonstrated stage I breast cancer detection sensitivity of 90% and ductal carcinoma in situ (DCIS)...

EpiBiologics Advances Degraders of Membrane-Bound Proteins

EpiBiologics, a preclinical stage company advancing new bispecific antibody therapeutics for extracellular protein degradation, is presenting data today on its EpiTAC protein degraders in oncology demonstrating robust in vivo anti-tumor activity and survival benefit. EpiTAC bispecific antibodies...

Hydronovo ITP receives $2.3 million CIRM Translational Research Grant

C-DOCTOR Interdisciplinary Translational Project Team, Hydronovo, received a $2.3 million California Institute for Regenerative Medicine (CIRM) Translational Stage research grant to fund the development of their small molecule therapy and related translational activities.

Sira Medical Wins FDA Clearance for Augmented Reality Preoperative Surgical Planning Software

The U.S. Food and Drug Administration granted Sira Medical clearance for its augmented reality preoperative surgical planning application, which provides clinicians with advanced imaging to assist in making key patient management decisions.

Nested Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NST-628, a Novel Pan-RAF/MEK Molecular Glue

Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for NST-628 for the treatment of patients...

J&J and Trial Library expand partnership on recruitment tools aimed at diversity

Johnson & Johnson Innovative Medicine and Trial Library have expanded a partnership to integrate the latter's clinical trial discovery platform into the pharma’s oncology clinical development and medical affairs programs. In a March 21 press release about the development, Trial Library CEO and...

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, reflects enthusiasm for Siolta's approach to developing live microbiome-based therapeutics and involved all existing...

Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders

Turbocharged CAR-T cells melt tumours in mice — using a trick from cancer cells

Immune cells armed with a mutation first identified in cancer cells gain potency but don’t turn cancerous themselves. “Natural T-cell function isn’t good enough. We need to explore the extremes of T-cell function,” says Kole Roybal, an immunologist at the University of California, San Francisco,...